Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors
Why invest in FBDU?
Flying Brands Ltd: THE INVESTMENT CASE

Flying Brands on track for successful commercial roll-out of StoneChecker

Flying Brands has signed a deal for the sale and distribution of its StoneChecker software in South Korea
Flying Brands
INVESTMENT OVERVIEW: FBDU The Big Picture
The StockChecker software provides a detailed analysis of kidney stones

Flying Brands Ltd (LON:FBDU) has secured its first major marketing and distribution contract for its kidney stone medical imaging software.

The medical and software company’s StoneChecker Software Ltd subsidiary has signed a deal with Korea Computer Motion ISG, which will sell and distribute the software in South Korea.

The software produces a detailed analysis of kidney stones to help physicians to decide which form of treatment would be most effective on a particular patient.

Nick Stevens, the chief executive officer of StoneChecker, said the distribution agreement would support the expansion of the software in the rapidly growing South Korean medical imaging market.

“We are confident that by working with an experienced team led by the CEO Jacob Woo, who has a great understanding of the market and customer base, we stand to increase StoneChecker's revenue potential, market reach and meet our customers' needs," Stevens said.

Woo said the StoneChecker software addresses a big gap in the urology-radiology market.

“StoneChecker is already attracting a lot of interest amongst the top university hospitals around the world and in South Korea (potential-customers). I anticipate a very successful business relationship and rapidly increasing StoneChecker software sales. Our team has a first-class reputation amongst radiologists and clinicians in the region, and offers unrivalled in-depth market-access and know-how in South Korea," Woo said.

StockChecker on track for European roll-out

In December, the company announced that the StockChecker software obtained a CE mark, meaning it met various requirements of the Medical Device Directive and satisfied the European Union’s quality, performance and safety standards.

The CE mark paved the way for the roll-out of the product across Europe.

"Obtaining a CE mark for StoneChecker Software's first product comfortably before the end of the year target has been a significant accomplishment for the agile multidisciplinary Stone Checker team,” said Flying Brands chief executive Trevor Brown.

 “I share the team's excitement as we prepare to approach the markets now available to us.”

StockChecker well-received by clinicians

The group completed prototype testing and evaluation of the software in October. 

At the time, Flying Brands said the semi-automatic calculation of important clinical information had been well received by clinicians.

“Urologists and radiologists appreciated the easy click process, the display of important clinical information such as stone to skin-surface distance and the map of stone density architecture on CT [computed tomography],” the company said.

The company had contracted with a specialist medical imaging software development company in North America to produce StoneChecker.

The North American contract manufacturer delivered the StoneChecker software prototype for testing in September.

Flying Brands expects approval from the US Food and Drug Administration (FDA) in the second quarter of 2018.

Flying Brands in acquisition talks

In February, the group confirmed that it was in advanced talks to buy an undisclosed North American medical imaging software and analytics company.

The AIM-listed firm said the acquisition target owns FDA approved medical imaging software using artificial intelligence techniques complementary and synergistic to those of Flying Brands.

The consideration payable is expected to be about £500,000, the majority of which would be satisfied in Flying Brands' shares.

“There can be no certainty that the possible acquisition will proceed as no binding agreement has been reached. Furthermore, the Company does not have any certainty as to the final terms on which the possible acquisition would proceed,” the group said.

StonePrevent

Flying Brands has also continued to make progress with its StonePrevent product, a screening programme that identifies or excludes causes of kidney stones.

At its half year results in August, the company said it has kicked off “potentially important” discussions with a single metabolic screening laboratory to explore the feasibility of outsourcing the technical metabolic screening processes to a single provider. 

“In a collaborative process, the StonePrevent product would add material value to the technical work of this global testing house while Stone Checker software would add significant healthcare experience and expertise,” it said.

View full FBDU profile View Profile

Flying Brands Ltd Timeline

Related Articles

H&T Pawnbrokers store
November 15 2017
“We have delivered a strong trading performance during the second half in the key segments of Pawnbroking, Retail and Personal Loans”
Flying Brands
March 07 2018
Flying Brands has signed a deal for the sale and distribution of its StoneChecker software in South Korea

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use